• Oryzon Genomics received Spanish authorization for VIVALDI, a CETLAM-sponsored Phase Ib trial in newly diagnosed patients with high-risk acute myeloid leukemia.
• The study will evaluate iadademstat with azacitidine and venetoclax in patient subgroups that respond poorly to standard treatment.
• Earlier ALICE-1 findings were published in The Lancet Haematology; preliminary ALICE-2 results showed encouraging activity and favorable tolerability.
• Final ALICE-2 results will be presented at the 2026 American Society of Hematology annual meeting.
• VIVALDI will inform European planning for Phase III ALICE-3, whose launch is targeted for 2027, subject to regulatory agreement and financing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oryzon Genomics SA published the original content used to generate this news brief on November 03, 2026, and is solely responsible for the information contained therein.